Neovascularization and jeopardized immunity has been critically emphasized for the establishment of malignant progression. Lectins are the diverse class of carbohydrate interacting proteins, having great potential as immunopotentiating and anti-cancer agents. The present investigation sought to demonstrate the anti-proliferative activity of Dolichos lablab lectin (DLL) encompassing immunomodulatory attributes. DLL specific to glucose and mannose carbohydrate moieties has been purified to homogeneity from the common dietary legume D. lablab. Results elucidated that DLL agglutinated blood cells non-specifically and displayed striking mitogenicity to human and murine lymphocytes in vitro with interleukin (IL)-2 production. The DLLconditioned medium exerted cytotoxicity towards malignant cells and neoangiogenesis in vitro. Similarly, in-vivo anti-tumour investigation of DLL elucidated the regressed proliferation of ascitic and solid tumour cells, which was paralleled with blockade of tumour neovasculature. DLL-treated mice showed an up-regulated immunoregulatory cytokine IL-2 in contrast to severely declined levels in control mice. Mechanistic validation revealed that DLL has abrogated the microvessel formation by weakening the proangiogenic signals, specifically nuclear factor kappa B (NF-jB), hypoxia inducible factor 1a (HIF-1 a), matrix metalloproteinase (MMP)-2 and 9 and vascular endothelial growth factor (VEGF) in malignant cells leading to tumour regression. In summary, it is evident that the dietary lectin DLL potentially dampens the malignant establishment by mitigating neoangiogenesis and immune shutdown. For the first time, to our knowledge, this study illustrates the critical role of DLL as an immunostimulatory and anti-angiogenic molecule in cancer therapeutics.
Introduction
Tumours foster a tolerant microenvironment and the activation of plethoric immunosuppressive mechanisms, which may act in concert to counteract effective immune responses. The immunosuppressive tumour immune microenvironment evades T cell responses, either to avoid immune recognition or to disable effector T cells [1, 2] . This strategy by malignant cells to breach the immune surveillance mechanism of the host has been linked most decisively to cancer progression [3] . Hence, dampening the tumour immunosuppressive microenvironment by stimulating the innate anti-tumour immunity may be an effective approach to cancer treatment. Immunotherapy aimed at harnessing endogenous anti-tumour immunity by modifying immune regulatory mechanisms has shown promise in multiple tumour types [2] . In compliance with this, recent findings in 2014 indicated that a complete immunological manoeuvre through the manipulation of immune system has represented an effective and reproducible outcome successfully, leading to the regression of large tumours in humans [4] . These observations and experimental understanding has not only deviated from our fundamental view of cancer therapeutics but has also propelled forward the renaissance of immunomodulation in eliciting anti-tumour immune responses, thereby enabling immune-based therapies to join the mainstream of cancer treatment.
Tumour neovasculature, the blood vessels produced within malignant growth by chronically activated angiogenesis and an unbalanced mix of proangiogenic signals, are known to be highly indispensable, even at the microscopic premalignant phase of neoplastic progression [5] [6] [7] . Intensive basic research and clinical practice have accentuated the important correlation between immunomodulation and angiogenesis [8] . Substantial evidence indicates that immunological cells such as T cells and certain immunoregulatory cytokines have shown the capacity to enhance immune response sufficiently to induce cancer remissions and inhibit tumour angiogenesis [9] [10] [11] . This suggests that a combinatorial approach encompassing anti-angiogenic and immunostimulatory perspectives has significant implications in the design of dynamic immunotherapeutic strategies for treating malignancies [11] .
Lectins are the ubiquitous and diverse class of haemagglutinating proteins of non-immune origin that bind stereospecifically to cell surface glycan moieties [12] [13] [14] . The lectin interactions on immune cell surfaces trigger signal transduction and the production of various beneficial cytokines, due to which these proteins are taking the forefront in biological research [14, 15] . The presence of haemagglutinin in the dietary bean Dolichos lablab (common name: Hyacinth bean) has been known since 1964 [14, 16] . D. lablab lectin (DLL), of the leguminoseae category, belongs to the tribe Phaseoleae, which is demonstrated to be unique in its specificity for the monosaccharides glucose and mannose, unlike the other members of its tribe. Although DLL shares many biological activities with other legume lectins, especially with a prototype legume lectin concanavalin A (Con A), the complete primary sequencing of DLL elucidated several distinguishing features from those of other legume lectins [12] [13] [14] . Indispensable evidence from as early as the 1980s reported the mitogenic properties of mannoside-specific DLL towards lymphocytes [17] , but even after three decades there have been no significant translational investigations to date, in spite of its immunomodulatory and therapeutic possibilities. As legume lectins have received remarkable attention due to their potent anti-neoplastic activity [18] , in this present study, for the first time to our knowledge, we sought to investigate the pharmacological potential of immunostimulatory D. lablab lectin directed to glucose and mannose in evoking the antitumour response in murine models targeting critical invivo tumour angiogenic parameters. This current study, envisaging a dietary and natural immunomodulator, promises a future scenario in overcoming immunosuppression and promoting tumour regression.
Materials and methods

Materials
The materials used were lung adenocarcinoma (A549), cervical carcinoma (SiHa, CaSki) and Ehrlich ascites carcinoma (EAC) from the National Centre for Cell Science (NCCS), Pune, India; squamous cell carcinoma (A388) from the National Centre for Biological Science (NCBS), Bengaluru, India and murine Dalton's ascites lymphoma (DLA) cells, a kind gift from Dr Sathees C. Raghavan, Indian Institute of Science (IISc), Bengaluru, India; and human umbilical vascular endothelial cells (HUVEC), endothelial cell growth media (EGM), sodium bicarbonate (NaHCO 3 ), cyanogen bromide (CNBr) activated Sepharose 4B, matrigel [extracellular matrix (ECM) gel], hydron polymer poly-hydroxyethyl-methacrylate (poly-HEMA), Ficoll histopaque, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide (MTT), anti-vascular endothelial growth factor (VEGF) and anti-mouse/rabbit immunoglobulin (Ig)G antibodies, protease inhibitor cocktail and Freund's adjuvants were obtained from Sigma-Aldrich (St Louis, MO, USA), anti-IL-2, anti-hypoxia inducible factor 1a (HIF-1a); anti-MMP-2 and 9 antibodies from Santa Cruz Laboratories (Santa Cruz, CA, USA); anti-nuclear factor kappa B (NF-jB), anti-IjB and anti-b-actin from BD Biosciences (San Jose, CA, USA); RPMI medium, antibioticanti-micotic solution, fetal bovine serum (FBS) from Invitrogen (Carlsbad, CA, USA); anti-CD-31 antibody and immunostaining kit from Leica Biosystems (Wetzlar, Germany). Schiff 's fuchsin-sulphite reagent, ovalbumin, amethyl mannoside (aMM) and other carbohydrates were from HiMedia Laboratories, India. Prestained protein marker was obtained from New England Biolabs (Ipswich, MA, USA); cell culture plastic wares were from Eppendorf (Hamburg, Germany); all the other chemicals used were of analytical grade. Fertilized hen's eggs were procured from a local farmhouse in Shivamogga, India. Photographs were taken using a Sony Steady Shot DSC-W610 camera. All the angiogenesis images were analysed by ImageJ software (NIH, Bethesda, MD, USA).
Purification and characterization of D. lablab lectin (DLL)
D. lablab lectin (DLL) was purified from the seeds of D. lablab by affinity chromatography, as described previously
by Mo et al., with slight modifications [19] . Briefly, the dried bean flour of D. lablab was extracted at 4 C with 10 mM phosphate-buffered saline (PBS) pH 7Á4. After subjecting to ammonium sulphate precipitation (20-60% saturation), the filtrate was dialysed and the clear dialysate was applied onto the ovalbumin-conjugated Sepharose 4B column. The affinity-adsorbed lectin was eluted specifically with 0Á2 M a-methyl mannoside in PBS at a flow rate of 15 ml/h. The pure lectin fractions were pooled, dialyzed extensively against PBS and analysed by reducing 12% sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE). The gels were then subjected to Coomassie brilliant blue and periodic acid-Schiff (PAS) staining for protein band visualization and glycoprotein analysis, respectively [20] . The bands were documented using the Bio-Rad Gel Documentation TM XR 1 imaging system. Polyclonal antibodies against purified DLL were raised in New Zealand White (NZW) rabbits in accordance with standardized protocols [21] . The immunoreactivity of rabbit polyclonal anti-serum was assessed by immunoblotting and double immunoprecipitation assays.
Agglutination and carbohydrate inhibition assay
Haemagglutination assay (HA) was carried out using trypsinized 2% chick, rabbit and human blood (types A, B, AB and O) erythrocyte suspension, as described previously [20] . Informed consent was obtained from all healthy human volunteers (age range 5 20-30 years) for obtaining peripheral venous blood. Briefly, 100 ll of erythrocytes suspension was added to an equal volume of serially diluted protein solution in a concavity agglutination plate, mixed gently and incubated at 378C for 1 h to visualize the agglutination. Carbohydrate-mediated HA inhibition was assessed by performing haemagglutination assay in the preincubated DLL with serially diluted sugars and glycoproteins [20] .
Leucoagglutination assay was carried out using human peripheral blood lymphocytes (PBLs) that were separated using Ficoll-Hypaque and density gradient centrifugation, as described previously [21] . The separated lymphocytes (100 ll) in 10 mM PBS were then added to an equal volume of DLL in a concavity agglutination plate, mixed gently and incubated at 378C for 1 h. Cell agglutinations were visualized using optical light microscopy and photographed.
Lymphocyte mitogenicity assay
Human PBLs, murine splenocytes and thymocytes were isolated and cultured in complete RPMI medium in a humidified environment at 378C [21] . The human and murine lymphocytes were cultured separately in flatbottomed 96-well microtitre plates (200 ll of 2Á5 3 10 6 cells/ml) in a CO 2 incubator at 378C with 5% CO 2 . After 3 h incubation, the cells were treated with crude DLL extracts, DLL (0, 5 and 10 lg/ml of media) and reference mitogen Con A (0, 5 and 10 lg/ml) for 72 h and MTT assay was performed. Supernatants from 24 h DLL (10 lg/ml)-stimulated cultures were collected and used as conditioned media (DLL-CM) for further studies [17] .
Cell culture and in-vitro treatment
The cells A549, A388, SiHa, CaSki, DLA and EAC were grown in RPMI medium supplemented with 10% FBS, antibiotic-micotics and NaHCO 3 (0Á37%) and incubated at 378C in 5% CO 2 with 98% humidity. The antiproliferative effect of DLL (0-50 mg/ml) and DLL-CM (0-50%) for 48 h was evaluated by MTT, trypan blue and lactate dehydrogenase (LDH) release assays and IC 50 values were calculated. For every experiment 5-fluorouracil was used as a positive control. Each experiment was repeated a minimum of three times independently and analysed with an appropriate vehicle and positive control [22] .
Chorioallontoic membrane (CAM) assay DLL-and DLL-CM-mediated angiogenic responsiveness to the recombinant VEGF 165 (rVEGF 165 ) induced in-vivo CAM angiogenesis were studied as described previously [23] . Of note, DLL (10 lg/CAM) or DLL-CM (10 lg/ CAM) were added to the growing fertilized eggs (5th day) and changes in the vascularization patterns were examined and photographed.
Rat aortic ring assay
The effect of DLL and DLL-CM on neovessel sprouting was studied by culturing aortic explants in matrigel as per the previously described methods, with slight modifications [24] . Briefly, transverse sectioned thoracic aortas with 1 mm diameter were cultured in matrigel immersed with RPMI media in a humidified environment at 378C for 2 weeks. DLL (10 lg/ml) or DLL-CM (30%) was added directly to the culture media and allowed to diffuse into the gel. Cultures were investigated by inverted light microscopy (Olympus) at 310 optical magnification.
Capillary tube formation assay
Functional analysis of DLL and DLL-CM on endothelial cells for vascular tube formation was performed following previous methods, with slight modifications [25] . Briefly, 100 ll of 2 3 10 4 endothelial cells in EGM were seeded onto matrigel-coated 96-well plates followed by treatment with or without rVEGF 165 , DLL (10 lg/ml) and DLL-CM (30%). After 4-6 h of incubation at 378C with 5% CO 2, the cells were assessed for formation of capillary-like structures using an inverted light microscope (Olympus) at 310 optical magnification.
Immunomodulatory glc/man-directed DLL Transwell invasion assay
The cell invasion inhibitory effects of DLL and DLL-CM were investigated by Transwell invasion assay [26] . Briefly, the harvested A549 cells (3 3 10 4 ) in 200 ll of serum-free RPMI medium with or without DLL (10 mg/ml) and DLL-CM (30%), respectively, were added to the matrigel-coated upper chamber; 0Á6 ml of RPMI with 20% FBS was added to the lower compartment and the Transwell-containing plates were incubated at 378C and 5% CO 2 for 8 h. The invaded cells were stained with 0.1% crystal violet and were captured using a photomicroscope at 340 resolution.
In-vivo studies Animal tumour development and treatment. DLA cells were cultured by intraperitoneal (i.p.) transplantation to develop ascites tumour. After the fourth day of tumour growth, the mice were administered with three doses of DLL [0, 20 and 30 mg/kg body weight (b.w.) i.p., n 5 6] on every alternative day. Ascitic tumour parameters were noted. Solid lymphoma (DLS) was developed in mice by injecting the cells subcutaneously (s.c.) in the right hindlimb according to previously described methods [23] . After the visible development of the tumour, mice were administered with six doses of DLL (0, 20 and 30 mg/kg b.w. i.p., n 5 6) on alternate days and tumour progression was monitored. The number of animals that survived and the duration after the treatment regimen were documented in a separate analysis. Toxicological parameters were examined by measuring the hepatic catalase and lipid peroxidation [27] . To assess the physiological effect of DLL in normal mice, the serum of DLL-treated animals were subjected to liver and kidney function tests by measuring the levels of alkaline phosphatase (ALP), creatinine and urea [23] .
MVD evaluation in peritoneum. Microvessel density (MVD) was assessed in the peritoneal lining of control and treated ascitic lymphomas, as reported previously [28] . Briefly, after the treatment regimen as described above, the response of DLL to the tumour-induced neovessel formation in peritoneum lining was observed and documented. Further, peritoneal tissue sections were processed for haematoxylin and eosin (H&E) staining and the MVD/highpower field (HPF) was quantified manually.
ELISA. The in-vitro and in-vivo secretion of IL-2 levels and serum VEGF-A were quantified by enzyme-linked immunosorbent assay (ELISA). In brief, 100 ll of conditioned media or serum were coated in coating buffer at 48C incubated with anti-IL-2 or anti-VEGF-A, followed by reincubation with ALP-conjugated secondary antibody. IL-2 and VEGF-A was quantified by measuring absorbance at 405 nm by using p-nitrophenyl phosphate (PNPP) as substrate.
Matrigel plug assay. BALB/c mice were implanted with 0Á5 ml of matrigel 1 rVEGF 165 (10 ng/plug) mixture with or without DLL (10 lg/plug) in the right flank. After 7 days following the implantation procedure, matrigel implants were harvested and liquefied by incubation at 48C overnight in 300 ll PBS. Further, the angiogenesis was quantified by estimating haemoglobin content in implants, as per previous reports [29] .
Corneal neovascularization assay. The rat corneal micropocket assay was performed in Swiss albino Wistar rats, as described previously with slight modifications [30] . Briefly after anaesthetizing the animal, micropockets were created using the slit knife in cornea. Hydron pellets containing 10 ng/pellet of either rVEGF 165 plus or minus DLL (10 mg) were implanted into corneal pockets. After 6-8 days the eyes were examined for neovasculature and photographed. The corneas were then dissected and subjected to histopathological assessment.
Protein extracts and Western blotting
Protein extracts were obtained from DLA and DLS tumour tissues (in vivo) for Western blot analysis. The proteins (30 lg) were resolved by SDS-PAGE and transferred onto nitrocellulose membrane. After blocking with 3% BSA in Tris-buffered saline Tween 20 (TBST) (150 mM NaCl, 10 mM Tris and 0.025% Tween 20 in dH 2 O), immunoblot analysis was performed for HIF-1a, VEGF-A, MMP-2, MMP-9, NF-jB, inhibitory kappa B (I-jB) and b-actin proteins using appropriate primary/secondary antibodies in blocking buffer three times independently, as per the manufacturer's recommendations. Results were repeated to the control by using ImageJ software.
Gelatin zymogram
DLA ascitic secretions were subjected to gelatin zymography to quantify gelatinase activity of MMP-2 and MMP-9. Briefly, proteins of the whole cell lysate were resolved in 8% SDS-PAGE gels containing 0Á1% (w/v) gelatin and zymogram was developed, as reported previously [28, 31] . Inhibition of gelatin lysis zones were documented using the Bio-Rad Gel Documentation TM XR1 Imaging System.
Immunohistochemical (IHC) analysis
Immunological detection of CD31, HIF-1a, MMP-2, MMP-9 and NF-jB in the formalin-fixed sections of the peritoneum and solid tumour tissues of the control and DLL-treated animals was performed using the specific antibodies, as per the manufacturer's instructions. Observations were made using the EVOS imaging system (Life Technologies, Paisley, UK) under 320 brightfield objective and the changes in intensity of the antibody staining were evaluated [32] .
Statistics
The data were analysed and graphs were made using MS Excel version 8.1. Statistical significance was evaluated by one-way analysis of variance (ANOVA) followed by Student's t-test. Values were expressed as mean 6 standard error (s.e.m.). Values of *P< 0Á05 and **P < 0Á01 were considered statistically significant.
Results
Purified DLL specific to glucose/mannose agglutinates haemocytes and leucocytes D. lablab lectin was purified to the electrophoretic homogeneity from the crude D. lablab bean extract (Supporting information, Fig. S1a ). Molecular mass estimation by reducing SDS-PAGE revealed that purified DLL resolved into five bands comprising a (band 1-4) and b (band 5) subunits, with apparent molecular weight ranging from 10 to 22 kDa (Fig. 1a) , similar to previous reports [19] . The chromatographic component DLL was tested for the haemagglutination activity which agglutinated chick, rabbit and human erythrocytes irrespective of blood type (Fig.  1b) . Leucoagglutination assay deduced a clear agglutination of the cells mediated by DLL in the microscopic visualization (Fig. 1c,d ). The minimal concentration for DLL to provide a visible haemagglutination was observed to be $3 lg in human RBC suspension (Supporting information, 
DLL induces potent mitogenicity in human and murine lymphocytes with IL-2 synthesis
Human PBLs, murine splenocytes and thymocytes were subjected to DLL stimulation to investigate the lectins' Immunomodulatory glc/man-directed DLL immunoproliferative properties (Fig. 2a-c) . The purified DLL (5 and 10 lg/ml) triggered a potent and significant mitogenic response in both human (Fig. 2d ) and murine lymphocytes (Fig. 2e,f) in a dose-dependent manner, which is more strikingly equivalent to Con A. Upon treatment with DLL, formation of aberrant lymphocyte clusters were observed, which is reported to be one of the prerequisite events in the lymphocyte stimulation (Fig. 2a) . As can be seen in Fig. 2a-c , microscopic evaluation reveals a varied and distinctive pattern of cell cluster formation in human and murine lymphocytes by DLL. The proliferative index for control was taken as 1Á0 and others are represented as fold increase or decrease over the control. Supernatants from the DLL-stimulated cell cultures were subjected to the estimation of IL-2 secretions. Similar to the previous report [17] , DLL-stimulated lymphocytes showed increased IL-2 synthesis in optimal concentrations (Fig. 2g) .
DLL-CM displays cytotoxic and anti-angiogenic attribute in vitro
Compelling evidence from various experiments has indicated that T cells are essential for an anti-proliferative and anti-angiogenic immune response. As it is known that glucose/mannose-specific DLL is a potent T cell mitogen [17] , we attempted to understand the antiproliferative and neovessel inhibitory effect of DLL-CM and DLL in standard in-vitro assay systems. In-vitro cytotoxicity activity of DLL-CM, as verified by cytotoxic assays, elucidated a decreased cell viability of A549, A388, SiHa, CaSki, DLA and EAC cells, where DLL alone did not show significant cytotoxicity or sensitivity, as shown in Table 1 . With respect to the effect of DLL and DLL-CM on angiogenesis, results inferred that MVD counts in exovo CAM and rat aortic angiogenesis influenced by rVEGF 165 was regressed markedly by the conditioned medium (68Á8 and 77Á1%, respectively) (Fig. 3a,b) . Treatment with DLL displayed 28Á4 and 22Á7% inhibition of CAM vessel density and aortic sprouting, respectively, which is apparently 2Á4-and 3Á5-fold less than the effect of conditioned medium (Fig. 3d,e) . To further affirm the anti-angiogenic activity, DLL-CM was verified by tube formation assay, which indicated a decreased tubeforming efficiency by 71Á3%, whereas DLL alone showed very negligible inhibition (Fig. 3c,f) . 
DLL impedes proliferation of murine ascitic and solid lymphoma tumour in vivo through immunomodulation
IL-2 is an immunoregulatory cytokine possessing antitumour activity [4] . Our observations and previous report indicate [17] that DLL stimulates the immune system through the secretion of IL-2 (Fig. 2g) . This has prompted us to investigate the effect of lectins in mitigating the progression of malignant cells in in-vivo murine ascitic and solid lymphoma tumour models. Results inferred that, in ascites tumour, administration of DLL resulted in significant diminution of tumour growth by 71Á8 and 82Á6% in varying concentrations (Supporting information, Fig. S2a ). Decisive evidence has indicated that DLL treatment has impacted negatively the various tumorigenic parameters, such as cell count and ascites secretion, in a dosedependent manner (Supporting information, Fig. S2b,c) . Moreover, survival analysis after the treatment regimen showed an approximate 2Á1-2Á5-fold prolonged lifespan, although a moderate recurrence ($10%) was observed, as analysed by body weight index (Supporting information, Fig. S2d ).
The tumour inhibitory potential of DLL was reevaluated further in Dalton's lymphoma solid tumour in mice. Following six consecutive DLL administrations on alternate days, there was considerable dose-dependent growth inhibition. The dissected tumour in the control weighed 17 g, whereas in treated mice it was 2Á61-3Á12-fold less than that of control at varying concentrations, thereby providing a clear perspective on the regression of tumour growth (Fig. 4a-e) . As in the ascites model study, DLL was able to extend the animals' lifespan from 45 to 98 and > 120 days (Fig. 4f) . However, oral administration of DLL after tumour onset did not produce the same tumour inhibitory results (data not shown). As DLL-CM exerted cytotoxicity in vitro (Table 1) , the immunomodulatory implications of DLL in endogenous systems were evaluated. Interestingly, concurrent to the in-vitro conditions, DLL up-regulated the serum IL-2 by twofold in tumour mice to that of control (Fig. 4i) . Furthermore, histopathological and gross examinations of internal organs showed no toxicity after DLL treatment (Supporting information, Fig. S3a-c) . Biochemical evaluation of liver enzymes revealed a decreased lipid peroxidation and elevated catalase activity upon DLL treatment (Fig. 4g,h ). Serological and haematological examination produced normal values after DLL treatment in normal non-tumour-bearing mice, indicating limited secondary complications (data not shown).
DLL deters tumour-reliant and independent neovascularization in rodents
Tumour development induces an early angiogenesis response, which is a critical and rate-limiting event in tumour progression [5, 6] . Hence, modalities blocking neovascular sprout are of particular interest in oncolytic strategies. Because we observed DLL-CM inhibiting angiogenesis in vitro (Fig. 3) , DLL was investigated for its deterrent effect on tumour-induced angiogenesis in murine ascites and solid lymphoma. Visible observation demonstrated that DLL decreased the development of ascitic lymphoma-induced peritoneal angiogenesis considerably by 1Á.21-1Á64-fold compared to the control (Fig. 5a ). Measurement of microvascular density (MVD) by H&E and anti-CD31 immunostained histological sections again validated that DLL restricted the MVD/HPF to 28Á8 6 1Á2 and 24Á32 6 2Á6 in 20 and 30 mg/kg concentrations, respectively, compared to the untreated mice (57 6 6Á2, Fig.  5b,c) . Similarly, the implication of DLL in blocking the tumour vessel density was studied further by employing Dalton's lymphoma solid tumours, which were subjected to histological and IHC studies. The results show that DLL lowered the MVD/HPF drastically, by $56 and $72% at 20 mg/kg b.w. and 30 mg/kg b.w., respectively, to that of control (Fig. 5d,e) . It should be noted that the decreased tumour MVD concurred with the regressed tumour volume and prolonged survival in the DLL group (Fig. 5f) .
To examine the angiopreventive effect of DLL in nontumour systems, lectin was subjected to rVEGF 165 -induced angiogenesis in vivo. The results indicated that DLL arrested the corneal angiogenesis substantially in rats (Fig.  5f) , with the MVD count reduced by 1Á43-fold compared to the rVEGF 165 -treated control, and this was confirmed further by histopathological examination of corneal sections (Fig. 5g) . Matrigel plug assay also displayed a similar 1Á35-fold reduction in rVEGF 165 -mediated vasculature in the DLL group compared to the control, as verified visibly and by haemoglobin estimation (Fig. 5h) . 36Á1 6 3Á7 5 Á3 6 0Á4** 4Á7 6 0Á8 SiHa 38Á3 6 3Á3 5 Á7 6 0Á3** 3Á7 6 0Á6* CaSki 37Á7 6 3Á1 6 Á1 6 0Á5* 4Á4 6 0Á4** DLA 38Á6 6 1Á5 6 Á4 6 0Á6* 2Á3 6 0Á3** EAC 44Á3 6 3Á5 7 Á3 6 0Á5* 4Á0 6 0Á2** 5-Fluorouracil is used a positive control. Cytotoxicity was measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide (MTT), Trypan blue and lactate dehydrogenase (LDH) release assays against each cell line in three independent (n 5 3) and values represent IC 50 by MTT. Dimethylsulphoxide (DMSO) is used as a vehicle control, which showed very negligible cytotoxicity. Values are indicated by mean 6 standard error (s.e.) and statistically significant values are expressed as *P < 0Á05 and **P < 0Á01.
Immunomodulatory glc/man-directed DLL 
DLL abrogates neovasculogenesis through altering the angiogenic signalling cascade in malignant cells
As the angiogenic capacity of tumour cells is largely attributable to the intrinsic genetic alterations that contribute to the establishment of the malignant phenotype [33] , DLLtreated cells were subjected to specific gene expression studies. DLL down-regulated various pro-angiogenic gene expressions, such as HIF-1a, VEGF-A, NF-jB, I-jB, MMP-2 and MMP-9 in both in-vivo ascitic and solid tumours compared to that of untreated tumours, as validated by Western blot (Fig. 6a,b) . Serological determination of secreted VEGF showed abridged levels in contrast to control (Fig. 6c) . In corroboration with these observations, gelatin zymography revealed a decreased level of MMP-2 and MMP-9 in DLL-treated ascitic secretions (Fig. 6d) . Counteraction of MMP-2 and MMP-9 expression resulted in the inhibition of invasive potency of A549 cells (Fig. 6e) . Immunohistochemical examination for the detection of HIF-1a, NF-jB, MMP-2 and MMP-9 corroborated the immunoblot, gelatin zymogram and invasion assay results further (Fig. 6f-j) . Fig. 3 . Anti-angiogenic activity of Dolichos lablab lectin-conditioned medium (DLL-CM) in in-vitro angiogenic assay models. Indirect angioinhibitory effect of DLL on various angiogenic systems in vitro. DLL-CM was the supernatant of DLL exposed to murine splenocytes after 24 h incubation. DLL-CM exhibits regressed angiogenesis in (a) ex-vivo chorioallontoic membrane (CAM) and (b) rat aortic angiogenesis assay. DLL directly exhibited only a minimal angiolytic effect. (c) DLL-CM exposed to human umbilical vein endothelial cells (HUVEC) cells inhibits the tube-forming efficiency. Pictographical representation of (d) ex-vivo CAM, (e) aortic ring angiogenesis and (f) tube formation assay. Data were represented as mean 6 standard error of the mean (s.e.m.) of three independent experiments. Statistically significant values are expressed as *P < 0Á05 and **P < 0Á01. [Colour figure can be viewed at wileyonlinelibrary.com].
Discussion
The legume lectin family is well known for its far-ranging biological functions [18] . The unique glycan-interacting potential of lectins on the immune cell surfaces ensues positive amplification of the immune system, thereby rendering them invaluable as tools in oncological and biomedical research [14, 15] . In line with previous reports [19] , we have purified a well-known glucose/mannosespecific D. lablab (DLL) lectin from the common dietary bean D. lablab of the leguminoseae family. The complete Immunomodulatory glc/man-directed DLL amino acid sequence of the lectin and its mitogenic attribute was reported long ago [14] but, despite its well-characterized and immunostimulatory properties there were only negligible reports promulgating its pharmacological implications. It is apparent that this immunomodulatory drug class has salience in oncotherapeutics, due to the notion that survival of malignant cells is dependent upon the microenvironment and evasion of the host's anti-tumour immune response [34] . In our study, screening against multiple cancer cells revealed that DLL failed to produce a significant inhibitory activity. Interestingly, DLL-CM, which expresses significant IL-2 levels, exhibited an anti-proliferative effect ( Table 1 ). The immunomodulatory implication of DLL prompted us to expand our investigation into Dalton's lymphoma, a reliable in-vivo tumour model which induces potential lethal effects in mice.
Results demonstrated that DLL effectively regressed pivotal tumour parameters of DLA/DLS in vivo with an extended life span (Supporting information, Figs S2 and S4 ).
There is a well-recognized relationship between antitumour activity and immunomodulation [35] . T cells are a central component of an adaptive immune system that is indispensable for immune system maintenance and immune surveillance to eliminate transformed cells [36] . However, chronic malignancy results in T cell exhaustion, with a major decline in IL-2 synthesis that leads to debilitating consequences regarding anti-tumour immunity [36] [37] [38] . As DLL is a potent T cell mitogen [17] , tumour inhibitory activity of the lectin (Supporting information, Figs S2 and S4) in our study suggests that the protein abrogates immunosuppression and T cell exhaustion in tumour mice. Our experimental evidence has indicated that DLL up-regulated IL-2 levels significantly in tumour mice compared to that of severely decreased levels in untreated mice (Fig. 4i) . This corresponds clearly with the regressed tumour growth in ascitic (Supporting information, Fig. S2 ) and solid tumour (Fig. 4) , thereby indicating that DLL has probably reversed the T cell exhaustion, consequentially breaking the IL-2 shutdown and eliciting an anti-tumour response.
Transformed cells do not become tumorigenic unless they acquire angiogenic potential [39] . Tumour neovasculaturization, one of the integral operations in malignant expansion, is marked by precocious capillary sprouting with convoluted, distorted and excessive vascular branching [5, 6, 40] . It is well known that Dalton's lymphoma induces massive peritoneal microvessel and vascular pathologies leading to invasiveness. Our observations showed that DL ascitic tumours and DL solid tumours showed enormous blood vessels which appeared to be highly disorganized and chaotic (Fig. 5a-e) . Convincing observations from our study have clarified that the DLL regimen potently regressed the tumour-induced neovasculature, which correlates positively with a reduced tumorigenic index (Fig. 4e) . Furthermore, earlier findings have provided evidence that among diverse roles, IL-2 displays antiangiogenic and tumour-regressive properties [41] . Collectively, our results demonstrate that elevated IL-2 cytokine has been attributed to the DLL-mediated anti-angiogenesis ( Fig. 5 ) and tumour regression in vivo (Supporting information, Figs S2 and S4) . Relative evidence could be observed from the angiopreventive and anti-proliferative effect of DLL-CM, with high IL-2 levels in in-vitro angiogenesis ( Fig. 3a-f ) and cytotoxicity assay systems (Table 1) , respectively. These observations explain that DLL has abrogated the tumour progression possibly through altering the immunological and angiogenic parameters.
Compelling reports provide a potential link between NF-jB activation and oncogenesis, which functions as a transcriptional regulator in a variety of malignancies as evidenced through the identification of cancer-specific, cancer-relevant gene targets controlled by NF-jB [1, 42] . In line with this, our experiments have demonstrated that both DL ascitic and solid tumours have shown elevated NF-jB levels with aberrant cellular proliferation and invasiveness (Fig. 6a,b ), but administration with DLL was able to reduce NF-jB expression substantially in tumour mice, which explains the potential role of lectin in altering the pro-oncogenic transcription factor, thus showing visible impairment in tumour progression (Fig. 4a,b) . One of the prominent features of the tumour microenvironment is the low oxygen tension or hypoxia which promptly induces HIF-1-mediated vascular switch, a prerequisite event for most malignancies and solid tumours to develop from a quiescent tumour into a more aggressive form [42] [43] [44] [45] . Our studies suggest that DLL treatment lowered the expression of the oxygen sensor HIF-1, a key regulatory factor involved in oncogenic conversion, and promoting neoangiogenesis in mice (Fig. 6a,b) . Reports show that constitutive HIF-1a and NF-jB activation in cancer cells has been shown to trigger autocrine of angiogenic chemokines, mainly VEGF, a pivotal factor for mitogenesis and capillary permeability of endothelial cells [42] [43] [44] [45] [46] [47] . Our experimental observations showed that DLL reduced VEGF expression, along with MMP-2 and MMP-9, thereby confirming the down-regulated proangiogenic signalling cascade in vivo (Fig. 6) . In support of this, decreased MMP expression is reflected in the retarded invasiveness of cancer cells (Fig.  6e) . Significantly, DLL retarded the tube formation of functional endothelial cells (HUVECs) and rVEGF 165 -induced neovessel formation in vitro (Fig. 3) . Moreover, DLL potentially reduced the peroxidized lipids in tumour mice (Fig.  4h) , which have been highly implicated in tumour angiogenesis and release of HIF-1a into the tumour microenvironment [48, 49] . Together, this evidence highlights DLL's potential in neovascularization inhibition.
Taken together, decisive observations demonstrate that dietary lectin DLL exerts potent anti-proliferative activity towards malignant cells. Immunopotentiating DLL impedes tumour progression specifically by antagonizing the neoangiogenesis formation in murine Dalton's lymphoma ascitic and solid tumours. This study highlights the critical role of dietary protein as an immunostimulatory and anti-angiogenic molecule targeting cancer cell progression (Fig. 7) . More in-depth investigations expediting molecular insights into tumour immunomodulation of this leguminous lectin could prove vital in making breakthrough improvements in cancer therapeutics. 
